Dr Chris Sutton

Biography

Chris Sutton obtained his B.Sc. degree and Ph.D. in Biochemistry from University of Liverpool, with combined studies in the Department of Plant Molecular Biology, University of California, Berkeley. He was then a Postdoctoral Research Scientist at the London School of Hygiene and Tropical Medicine, investigating the mechanisms of pathogenicity of Vibrio cholerae. He joined the premier of UK biotechnology company, Celltech Limited, as a Senior Scientist in Protein Biochemistry purifying novel proteins of therapeutic interest, and was later promoted to Group Leader of Analytical Biochemistry. With the emergence of mass spectrometry for protein characterisation, he moved to ThermoFinnigan and developed novel applications for matrix assisted laser desorption mass spectrometry (MALDI MS) including pioneering work in proteomics. He joined Kratos Analytical as MALDI MS Product Manager and was responsible for the marketing and promotion, including co-ordinating the research activity of a worldwide group of 25 application specialists who were developing MALDI MS solutions for the future. He was subsequently promoted to Business Manager for the product lines with a staff of 50, doubling revenues during this time to 10 million USD per annum. Since August 2005, Chris has joined the Institute of Cancer Therapeutics in the University of Bradford as Senior Lecturer in Proteomics Chemistry and Mass Spectrometry. With the support of Yorkshire Cancer Research, he has develop three key areas of research (1) identification of new proteins as candidate diagnostic biomarkers, (2) identification of proteins affected by the action of anticancer drugs and (3) identification of new target proteins for anticancer drug development. He has developed collaborations with academic groups in Hull, York, Sheffield and Leeds within the UK and Toronto, Cyprus, Pakistan internationally.  

Professional activities